Pei Dong Wu
Keine laufenden Positionen mehr
Karriereverlauf von Pei Dong Wu
Ehemalige bekannte Positionen von Pei Dong Wu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AIRNET TECHNOLOGY INC. | Finanzdirektor/CFO | 01.06.2014 | 01.03.2019 |
VIMICRO INTERNATIONAL CORPORATION (ADR) | Finanzdirektor/CFO | 07.10.2011 | 01.03.2012 |
CHINA MED | Finanzdirektor/CFO | 21.12.2009 | 21.12.2009 |
Dragon Bay Capital LLC | Präsident | 20.01.2009 | 01.12.2009 |
CHINA NATURAL GAS, INC. | Finanzdirektor/CFO | 23.10.2008 | 30.04.2009 |
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - | |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 25.05.2018 | - |
Independent Dir/Board Member | 25.05.2018 | - |
Ausbildung von Pei Dong Wu
Indiana University | Graduate Degree |
University of China | Graduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
China University of Political Science & Law | Graduate Degree |
Zhengzhou University | Undergraduate Degree |
Statistik
International
China | 10 |
Vereinigte Staaten | 4 |
Operativ
Director of Finance/CFO | 4 |
Graduate Degree | 3 |
Director/Board Member | 2 |
Sektoral
Consumer Services | 6 |
Health Technology | 3 |
Industrial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
CHINA NATURAL GAS, INC. | Industrial Services |
CHINA MED | Health Technology |
AIRNET TECHNOLOGY INC. | Commercial Services |
Private Unternehmen | 4 |
---|---|
Vimicro Corp.
Vimicro Corp. SemiconductorsElectronic Technology Vimicro International Corp. provides video surveillance technology solutions. The firm engages in the development and marketing of mixed signal semiconductor products and system-level solutions that enable image processing capabilities in a variety of products for the consumer electronics, communications and surveillance markets. It operates through two segments: Personal Computer Multimedia Processors and Security & Surveillance Products. The Personal Computer Multimedia Processors segment is engaged in the design, manufacture and sale of multimedia processors, including PC and embedded notebook camera multimedia processors and the multimedia processors. The Security & Surveillance Products segment is engaged in the design, manufacture and sale of security and surveillance products. The company was founded by Zhong Han Deng and Zhao Wei Jin in 1999 and is headquartered in Beijing, China. | Electronic Technology |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Dragon Bay Capital LLC |
- Börse
- Insiders
- Pei Dong Wu
- Erfahrung